Nukinori Akiyama

Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.

M. Ohmori, Hiroki Nishii, K. Morikami, 2016, Journal of medicinal chemistry.

YES1 is a targetable oncogene in cancers harboring YES1 gene amplification.

H. Koyano, N. Ishii, Haruhiko Sato, 2019, Cancer research.

Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1

M. Aoki, N. Ishii, T. Tsukaguchi, 2015, Molecular Cancer Therapeutics.

Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer

M. Aoki, N. Ishii, T. Mio, 2018, Molecular Cancer Therapeutics.

ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor

M. Aoki, N. Ishii, Y. Aoki, 2015, Molecular Cancer Therapeutics.

The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor

K. Morikami, H. Shindoh, N. Ishii, 2014, Molecular Cancer Therapeutics.

Small Molecule Therapeutics The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH 5183284 / Debio 1347 , a Novel Selective FGFR Inhibitor

K. Morikami, H. Shindoh, N. Ishii, 2014 .